We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intellia Therapeutics Inc | NASDAQ:NTLA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.18 | 5.07% | 24.45 | 4.90 | 28.97 | 24.99 | 23.42 | 24.44 | 1,294,988 | 05:00:07 |
Details of the presentation are as follows:
Jefferies Gene Editing/Therapy SummitDate: Tuesday, October 11, 2016 Location: New York, New YorkTimes: Panel discussion at 10:00 am ET with company presentation to follow at 2:00 pm ET.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 jenn.smoter@intelliatx.com Investor Contacts: John Graziano Trout Group +1 646-378-2942 jgraziano@troutgroup.com Chad Rubin Trout Group +1 646-378-2947 crubin@troutgroup.com
1 Year Intellia Therapeutics Chart |
1 Month Intellia Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions